Business Description
Novartis AG
ISIN : CA66989X1033
Share Class Description:
FRA:NOT0: Novartis CDR (CAD Hedged)Total Employee Number:
75,267Compare
Compare
Traded in other countries / regions
NOVN.SwitzerlandNVS.USA0QLR.UKNOT.Germany1NOVN.ItalyNVS.CanadaNVS.ArgentinaNOVNN.MexicoN1VS34.Brazil IPO Date
2025-02-27Description
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 1.22 | |||||
Debt-to-EBITDA | 2.07 | |||||
Interest Coverage | 14.16 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.64 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.8 | |||||
3-Year EBITDA Growth Rate | 14.3 | |||||
3-Year EPS without NRI Growth Rate | 30.1 | |||||
3-Year FCF Growth Rate | 6.9 | |||||
3-Year Book Growth Rate | -9.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.31 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.43 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.9 | |||||
9-Day RSI | 69.4 | |||||
14-Day RSI | 62.73 | |||||
3-1 Month Momentum % | -3.98 | |||||
6-1 Month Momentum % | 7.64 | |||||
12-1 Month Momentum % | 22.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.85 | |||||
Quick Ratio | 0.65 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 166.33 | |||||
Days Sales Outstanding | 58.98 | |||||
Days Payable | 118.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.98 | |||||
Dividend Payout Ratio | 0.4 | |||||
3-Year Dividend Growth Rate | 0.4 | |||||
Forward Dividend Yield % | 1.98 | |||||
5-Year Yield-on-Cost % | 2.3 | |||||
3-Year Average Share Buyback Ratio | 3.4 | |||||
Shareholder Yield % | 4.83 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.39 | |||||
Operating Margin % | 30.44 | |||||
Net Margin % | 23.94 | |||||
EBITDA Margin % | 39.6 | |||||
FCF Margin % | 28.24 | |||||
OCF Margin % | 33.91 | |||||
ROE % | 31.74 | |||||
ROA % | 12.28 | |||||
ROIC % | 13.88 | |||||
3-Year ROIIC % | -44.39 | |||||
ROC (Joel Greenblatt) % | 140.21 | |||||
ROCE % | 21.58 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 22.41 | |||||
Forward PE Ratio | 16.52 | |||||
PE Ratio without NRI | 22.41 | |||||
Shiller PE Ratio | 24.11 | |||||
Price-to-Owner-Earnings | 17.13 | |||||
PEG Ratio | 8.96 | |||||
PS Ratio | 5.36 | |||||
PB Ratio | 7.87 | |||||
Price-to-Free-Cash-Flow | 19 | |||||
Price-to-Operating-Cash-Flow | 15.82 | |||||
EV-to-EBIT | 19.98 | |||||
EV-to-Forward-EBIT | 16.65 | |||||
EV-to-EBITDA | 15.17 | |||||
EV-to-Forward-EBITDA | 14.63 | |||||
EV-to-Revenue | 6 | |||||
EV-to-Forward-Revenue | 5.85 | |||||
EV-to-FCF | 21.21 | |||||
Price-to-GF-Value | 1.21 | |||||
Price-to-Projected-FCF | 1.77 | |||||
Price-to-Median-PS-Value | 1.32 | |||||
Earnings Yield (Greenblatt) % | 5.01 | |||||
FCF Yield % | 5.36 | |||||
Forward Rate of Return (Yacktman) % | 5.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Novartis AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 48,630.528 | ||
| EPS (TTM) (€) | 0.879 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 19.76 | ||
| 14-Day RSI | 62.73 | ||
| 14-Day ATR (€) | 0.237803 | ||
| 20-Day SMA (€) | 17.375 | ||
| 12-1 Month Momentum % | 22.46 | ||
| 52-Week Range (€) | 13 - 18.8 | ||
| Shares Outstanding (Mil) | 13,030.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-27 | In 117 days | ||
| Third quarter earnings results for 2026 | 2026-10-27 | In 117 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-21 | In 19 days | ||
| Second quarter earnings results for 2026 | 2026-07-21 | In 19 days | ||
| First quarter earnings conference call for 2026 | 2026-04-28 14:00 | 16.60 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 16.60 (+0.00%) | ||
| CAD 0.566156 Cash Dividend | 2026-03-11 | 18.30 (+0.00%) | ||
| General meeting for 2026 | 2026-03-06 10:00 | 18.80 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-04 14:00 | 16.80 (+0.00%) | ||
| Annual report for 2025 | 2026-02-04 | 16.80 (+0.00%) |
Show
Entries
Novartis AG Frequently Asked Questions
What is Novartis AG(FRA:NOT0)'s stock price today?
The current price of FRA:NOT0 is €18.20. The 52 week high of FRA:NOT0 is €18.80 and 52 week low is €13.00.
When is next earnings date of Novartis AG(FRA:NOT0)?
The next earnings date of Novartis AG(FRA:NOT0) is 2026-07-21.
Does Novartis AG(FRA:NOT0) pay dividends? If so, how much?
The Dividend Yield % of Novartis AG(FRA:NOT0) is 1.98% (As of Today), Highest Dividend Payout Ratio of Novartis AG(FRA:NOT0) was 1.19. The lowest was 0.33. And the median was 0.84. The Forward Dividend Yield % of Novartis AG(FRA:NOT0) is 1.98%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Novartis AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers